{"id":"atovaquone-oral-suspension","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Nausea"},{"rate":"3-8","effect":"Headache"},{"rate":"3-8","effect":"Vomiting"},{"rate":"3-8","effect":"Abdominal pain"},{"rate":"2-5","effect":"Fever"}]},"_chembl":null,"_dailymed":{"setId":"4a2e2c4b-85aa-9b30-e063-6294a90a7bd9","title":"ATOVAQUONE ORAL SUSPENSION (ATOVAQUONE) SUSPENSION [KESIN PHARMA CORPORATION]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atovaquone is a hydroxynaphthoquinone that selectively targets the mitochondrial respiratory chain of Plasmodium species and Pneumocystis jirovecii. By inhibiting the cytochrome bc1 complex (Complex III), it prevents electron transport and collapses the mitochondrial membrane potential, leading to rapid ATP depletion and parasite death. This mechanism is particularly effective against these organisms while having minimal impact on human mitochondrial function due to structural differences in the target enzyme.","oneSentence":"Atovaquone inhibits the cytochrome bc1 complex in the mitochondrial electron transport chain of parasites, disrupting energy production and causing parasite death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:56:08.959Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment"},{"name":"Malaria (Plasmodium falciparum) treatment, particularly in combination with proguanil"}]},"trialDetails":[{"nctId":"NCT04648033","phase":"PHASE1","title":"Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-12-07","conditions":"Locally Advanced Non-Small Cell Lung Cancer","enrollment":21},{"nctId":"NCT06624371","phase":"PHASE1","title":"Atovaquone Combined With Radiation in Children With Malignant Brain Tumors","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-03-28","conditions":"High-grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma","enrollment":18},{"nctId":"NCT01858831","phase":"PHASE1","title":"Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04","conditions":"Malaria","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20221122","type":"SUPPL","sponsor":"ABHAI LLC","applicationNumber":"ANDA210510"},{"date":"20190531","type":"ORIG","sponsor":"ABHAI LLC","applicationNumber":"ANDA210510"}],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Wellvone"],"phase":"marketed","status":"active","brandName":"Atovaquone Oral Suspension","genericName":"Atovaquone Oral Suspension","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atovaquone inhibits the cytochrome bc1 complex in the mitochondrial electron transport chain of parasites, disrupting energy production and causing parasite death. Used for Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Malaria (Plasmodium falciparum) treatment, particularly in combination with proguanil.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}